Drug

EyePoint's DURAVYU Misses Primary Endpoint in Phase III LUCIA Trial for Wet AMD – Non‑Inferiority vs. Aflibercept Not Achieved; Key Secondary Endpoints Met
Betta PharmaceuticalsClinical trial results

EyePoint’s DURAVYU Misses Primary Endpoint in Phase III LUCIA Trial for Wet AMD – Non‑Inferiority vs. Aflibercept Not Achieved; Key Secondary Endpoints Met

Betta Pharmaceuticals (SHE: 300558) announced that its partner EyePoint Pharmaceuticals (NASDAQ: EYPT) disclosed data from LUCIA, the second pivotal Phase III clinical trial evaluating EYP‑1901 (DURAVYU), an investigational vorolanib ophthalmic…

Eli Lilly's Omvoh Delivers First One‑Year Phase 3 Readout in Pediatric Ulcerative Colitis – 50 % Clinical Remission at Week 52 in SHINE‑2

Eli Lilly’s Omvoh Delivers First One‑Year Phase 3 Readout in Pediatric Ulcerative Colitis – 50 % Clinical Remission at Week 52 in SHINE‑2

AbbVie's Dual‑Targeting ABBV‑466 Outperforms Both Monotherapies in Crohn's Disease – Higher Endoscopic Remission Rates at Week 12 in TARGET‑CD Study

AbbVie’s Dual‑Targeting ABBV‑466 Outperforms Both Monotherapies in Crohn’s Disease – Higher Endoscopic Remission Rates at Week 12 in TARGET‑CD Study

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Harbour BioMed Reports Phase II Success of Porustobart in MSS mCRC
CancerClinical trial results

Harbour BioMed Reports Phase II Success of Porustobart in MSS mCRC

GFH375 Enters Phase Ib/II at Peking University: GenFleet Targets KRAS G12D
CancerClinical trial approval / initiation

GFH375 Enters Phase Ib/II at Peking University: GenFleet Targets KRAS G12D

BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4/6 IN BRIGHT‑3: Xuanzhu Biopharma Announces Interim Phase III Results at ESMO 2025
Academic conferenceCancer

BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4/6 IN BRIGHT‑3: Xuanzhu Biopharma Announces Interim Phase III Results at ESMO 2025

Sichuan Biokin Secures NMPA Approval for BL‑M24D1 ADC, Targeting Relapsed Hematologic and Solid Tumors
ADC / XDCBiokin Pharmaceutical

Sichuan Biokin Secures NMPA Approval for BL‑M24D1 ADC, Targeting Relapsed Hematologic and Solid Tumors

Show More